Frazier Management adds Lion Biotechnologies Inc (LBIO) to its portfolio

Lion Biotechnologies Inc (LBIO) : Frazier Management added new position in Lion Biotechnologies Inc during the most recent quarter end. The investment management firm now holds 774,720 shares of Lion Biotechnologies Inc which is valued at $7,135,171 , the company said in a statement filed on Aug 9, 2016 with the SEC.Lion Biotechnologies Inc makes up approximately 6.27% of Frazier Management’s portfolio.

Other Hedge Funds, Including , Geduld E E added LBIO to its portfolio by purchasing 10,000 company shares during the most recent quarter which is valued at $89,100. Lion Biotechnologies Inc makes up approx 0.12% of Geduld E E’s portfolio. Quantitative Investment Management added LBIO to its portfolio by purchasing 14,500 company shares during the most recent quarter which is valued at $133,690. Lion Biotechnologies Inc makes up approx 0.01% of Quantitative Investment Management’s portfolio. Quantitative Systematic Strategies added LBIO to its portfolio by purchasing 22,452 company shares during the most recent quarter which is valued at $198,476. Lion Biotechnologies Inc makes up approx 0.09% of Quantitative Systematic Strategies’s portfolio.Cutler Group Lp boosted its stake in LBIO in the latest quarter, The investment management firm added 1,883 additional shares and now holds a total of 4,883 shares of Lion Biotechnologies Inc which is valued at $40,724.

Lion Biotechnologies Inc closed down -0.14 points or -1.54% at $8.96 with 1,51,888 shares getting traded on Wednesday. Post opening the session at $9.1, the shares hit an intraday low of $8.82 and an intraday high of $9.15 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Lion Biotechnologies Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Lion Biotechnologies Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.